The Convergent competitive advantage 

The Convergent platform creates differentiated value across clinical, operational, and economic dimensions. Convergent’s radiation source is a CT tube (kV range), enabling a much lower total cost of ownership. There is no need for high density concrete, steel bunkers or $1 million+ in infrastructure expenses.

Potential re-irradiation for intricate indications such as intracranial and head & neck

Potential for mobile treatment of pre-cancer lung nodules